Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5462375 | 0.91 | TLR7 (0.46) | TLR7ADORA2AADORA1SLC7A5TMIGD3 | |
| SCHEMBL5464032 | 0.90 | TLR7 (0.47) | TLR7SLC7A5KDM4E | |
| SCHEMBL5467035 | 0.86 | TLR7 (0.49) | TLR7ADORA2AADORA1SLC7A5TMIGD3 | |
| SCHEMBL2060301 | 0.85 | TLR7 (0.48) | TLR7ADORA2AADORA1SLC7A5TMIGD3 | |
| SCHEMBL5468453 | 0.83 | TLR7 (0.44) | TLR7ADORA2AADORA1SLC7A5TMIGD3 | |
| SCHEMBL2060315 | 0.82 | ADORA2A (0.38) | TLR7ADORA2AADORA1TMIGD3ADORA2B | |
| SCHEMBL5467025 | 0.82 | TLR7 (0.45) | TLR7ADORA2AADORA1 | |
| SCHEMBL2060118 | 0.81 | TLR7 (0.69) | TLR7 | |
| SCHEMBL5464183 | 0.81 | TLR7 (0.55) | TLR7ADORA2AADORA1 | |
| SCHEMBL5470899 | 0.81 | TLR7 (0.59) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225303-A1 | 8-Oxoadenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070225303-A1 | 8-Oxoadenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070225303-A1 | 8-Oxoadenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1728792-A1 | 8-OXOADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225303-A1 | 8-Oxoadenine Compound | TLR7, CCR8, TLR8 | TLR7 1/4885ADORA2A 22/4885ADORA1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.